Targeted therapy after liver transplant for high-risk liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a targeted therapy (lenvatinib) given after a living-donor liver transplant to prevent high-risk liver cancer from coming back. It is for people whose cancer is aggressive or did not respond well to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are getting a liver transplant from a living donor (LDLT).
- You can start targeted therapy within 1-2 months after transplant.
- Your anti-rejection medicines will include tacrolimus or cyclosporine, mycophenolate mofetil, and sirolimus.
- Your cancer is considered high-risk (positive PET scan, tumors beyond UCSF criteria, poorly-differentiated, or poor AFP response).
- You are willing to use effective birth control if you or your partner can become pregnant.
- You do not have severe heart disease, HIV, active infections, or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy (lenvatinib) to standard chemotherapy after a liver transplant can help prevent liver cancer from coming back. It may be an option for patients who have had a transplant and want to reduce the risk of recurrence.
This trial tests whether taking lenvatinib after liver cancer surgery can lower the chance of the cancer coming back. It is for people who have a high risk of recurrence and have recently had their liver tumor completely removed.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether adding targeted radiation therapy can help people with liver cancer that cannot be surgically removed. It is for people who have already received a combination of TACE, lenvatinib, and sintilimab and whose tumors have not grown.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
Hear when a new High Risk of Recurrence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.